Install
The analyzed dataset included over 200,000 patients with vitiligo to find trends in diagnosis, treatment, and more. The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval. Serota and other field experts discussed best practices as well as new t
- 44articles · 180d
- 2+ day agolatest article
- Mar 25, 2026earliest in window
- 84%with images
- 205avg words
- Medical 44
- Health 40
- Health & Wellness 37
- Beauty & Fitness 6
- Human Interest 2
- Computers & Electronics 1
- Education 1
- Science & Technology 1
- dermatology
- skin health
- 83rd american academy
- integument 2 phase 3 trials
- atopic dermatitis
- prior inadequate response
- patient reported outcomes
- including intertriginous areas
- pediatric patients 6 years
- moderate atopic dermatitis
- pediatric patients 9 years
- severe liver impairment
- common adverse reactions
- plaque psoriasis include diarrhea
- application site pain
- upper respiratory tract infection
- urinary tract infection
- tmt newswire
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Inflammatory Disease | Derm NP/PA Connect
1+ mon, 3+ week ago (1413+ words) This review of the latest dermatological studies includes insights on gut dysbiosis in inflammatory conditions, air pollution and vitiligo risk, emollient use in AD patients, and more. This review of the latest dermatological studies includes insights on a mobile AI…...
Understanding the Underlying Pathophysiology of Erythropoietic Protoporphyria
3+ mon, 3+ week ago (556+ words) Dermatology Times Understanding the Underlying Pathophysiology of Erythropoietic Protoporphyria - Disproportionate pain with absent or subtle skin findings commonly leads to misattribution, skepticism, and prolonged diagnostic delays, particularly in pediatric presentations after outdoor activity. - Fluorescent indoor lighting and operating room illumination…...
From AAD 2026 to Practice: Highlighting Key Clinical Advances
4+ mon, 5+ day ago (127+ words) New data unveiled at AAD 2026 emphasized the growing role of targeted immune modulation and systemic therapies in dermatologic care. Summer may be approaching, but Dermatology Times is still reminiscing about the endless data shared at the 2026 American Academy of Dermatology…...
Journal Digest: April 29, 2026
4+ mon, 1+ week ago (692+ words) Dermatology Times Clinical Case Reports | Skin Hyperpigmentation: An Under-Recognized Dermatological Clue to Vitamin B12 Deficiency A recent case report highlights cutaneous hyperpigmentation as an often-overlooked but potentially early sign of vitamin B12 deficiency. A 69-year-old man presented with symmetric hyperpigmentation of the…...
Bimekizumab Shows Durable Responses in Psoriasis and HS Through 3 Years
5+ mon, 1+ week ago (319+ words) Steven Daveluy, MD, reviews long-term trial data for bimekizumab in psoriasis and hidradenitis suppurativa presented at the 2026 AAD Annual Meeting. Long-term data for bimekizumab (Bimzelx; UCB) continue to show sustained efficacy in both psoriasis and hidradenitis suppurativa (HS), with no…...
AAD 2026: Dermatologist Calls for Greater Inclusion of Older Adults in Skin Disease Research
5+ mon, 1+ week ago (285+ words) Daniel C. Butler, MD, discusses the underrepresentation of older adults in dermatology trials and what a 3-system framework for itch means for clinical practice Butler's entry into itch research came through his broader interest in aging. The immune system, the nervous…...